J-Valve Transfemoral Pivotal Study

NAActive, not recruitingINTERVENTIONAL
Enrollment

194

Participants

Timeline

Start Date

October 17, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2031

Conditions
Aortic Valve RegurgitationAortic Valve Disease Mixed
Interventions
DEVICE

J-Valve Transfemoral (TF) System

Treatment includes using the J-Valve Transfemoral (TF) System, a transcatheter aortic valve replacement system that consists of the J-Valve TF Bioprosthesis and the J-Valve TF Delivery Device and Loading Accessories, during transcatheter aortic valve replacement (TAVR). The Edwards 16Fr eSheath+ Introducer Set may be used for the introduction and removal of the J-Valve TF System.

Trial Locations (18)

10467

Montefiore Medical Center, The Bronx

30308

Emory University Atlanta, Atlanta

34102

NCH Rooney Heart Institute, Naples

37205

Ascension St. Thomas West Hospital, Nashville

37232

Vanderbilt University Medical Center, Nashville

45219

The Lindner Research Center at The Christ Hospital, Cincinnati

48202

Henry Ford Hospital Detroit, Detroit

60611

Northwestern University Chicago, Chicago

63110

Washington University - Barnes-Jewish Hospital St. Louis, St Louis

67214

Ascension Via Christi, Wichita

70360

Cardiovascular Institute of the South, Houma

77004

HCA Houston Healthcare Medical Center, Houston

77030

Houston Methodist Hospital, Houston

85258

HonorHealth Research & Innovation Institute, Scottsdale

90048

Cedars Sinai, Los Angeles

98122

Swedish Heart & Vascular Research, Seattle

02114

Massachusetts General Hospital Boston, Boston

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Minneapolis Heart Institute Foundation

OTHER

collaborator

Cardiovascular Research Foundation, New York

OTHER

lead

JC Medical, Inc., an affiliate of Edwards Lifesciences LLC

INDUSTRY